You are here

Kısa süreli oral metilfenidat kullanımı ile ilişkili iskemik inme

Ischemic stroke associated with the use of short term oral methylphenidate

Journal Name:

Publication Year:

Keywords (Original Language):

Abstract (2. Language): 
Methylphenidate is a central nervous system stimulant used for the treatment of attention deficit hyperactivity disorder and narcolepsy. In this report, a 9-year-old boy with cerebral ischemic stroke developing after the short term use of oral methylphenidate is presented. The experience of our patient and a review of the literature suggest that consumption of oral methylphenidate may be a potential predisposing factor for stroke.
Abstract (Original Language): 
Metilfenidat, dikkat eksikliği-hiperaktivite hastalığı ve narkolepside kullanılan bir santral sinir sistemi stimülanıdır. Bu makalede, kısa süreli oral metilfenidat kullanımını takiben serebral iskemik inme gelişen 9 yaşında bir erkek çocuğu sunulmaktadır. Bizim hastamızdaki deneyimimiz ve literatür incelemesi, oral metilfenidat kullanımının inme için potansiyel predispozan bir faktör olabileceği fikrini desteklemektedir.
169-171

REFERENCES

References: 

1. Challman TD, Lipsky JJ. Methylphenidate: its pharmacology and uses. Mayo
Clin Proc 2000; 75: 711-721.
2. Jansen IH, Olde Rikkert MG, Hulsbos
HA, Hoefnagels WH. Toward individualized evidence-based medicine: five ''N
of 1'' trials of methylphenidate in geriatric patients. J Am Geriatr Soc 2001; 49:
474-476.
3. Johnson ML, Roberts MD, Ross AR,
Witten CM. Methylphenidate in stroke
patients with depression. Am J Phys Med
Rehabil 1992; 71: 239-241.
4. Hinkin CH, Castellon SA, Hardy DJ, et
al. Methylphenidate improves HIV-1
associated cognitive slowing. J
Neuropsychiatry Clin Neurosci 2001;
13: 248-254.
5. Glen MB. Methylphenidate for cognitive
and behavioral dysfunction after traumatic brain injury. J Head Trauma
Rehabil 1998; 13: 87-90.
6. Rozans M, Dreisbach A, Lertora JJ, Kahn
MJ. Paliative uses of methylphenidate in
patients with cancer: a review. J Clin
Oncol 2002; 20: 335-339.
7. Meririnne E, Kankaanpaa A, Seppala T.
Rewarding properties of Methylphenidate: sensitization by prior exposure to the drug and effects of dopamine
D1- and D2- receptor antagonists. J
Pharmacol Exp Ther 2001; 298: 539-550.
8. Koe BK. Molecular geometry of
inhibitors of the uptake of catecholamines and serotonin in synaptosomal preparations of rat brain. J
Pharmacol Exp Ther 1976; 199: 649-661.
9. Segal DS and Kuczenski R. Escalating
dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral profile. J Pharmacol Exp
Ther 1999; 291: 19-30.
10.Vastag B. Pay attention: ritalin acts much
like cocaine. JAMA 2001; 8: 22-29.
11.Kirkham FJ, Prengler M, Hewes DKM,
Ganesan V. Risk factors for arterial
ischemic stroke in children. J Child
Neurol 2000; 15: 299-307.
12.Citron BP, Halpern M, Mc Carron M, et
al. Necrotizing angiitis associated with
drug abuse. N Engl J Med 1970; 283:
1003-1011.
13.Rumbaugh CL, Bergeron TR, Scanlon
RL, et al. Cerebral vascular changes secondary to amphetamine abuse in the
experimental animal. Radiology 1971;
101: 345-351.
14.Rumbaugh CL, Fang HCH, Higgins
RE, et al. Cerebral microvascular injury
in experimental drug abuse. Invest
Radiol 1976; 11: 282-294.
15.Harrington H, Heller HA, Dawson D, et
al. Intracerebral hemorrhage and oral
amphetamine. Arch Neurol 1983; 40:
503-507.
16.Trugman JM. Cerebral arteritis and oral
methylphenidate. Lancet 1998; 1 (8585):
584-585.
17.Schteinschnaider A, Plaghos LL,
Garbugino S, et al. Cerebral arteritis following methylphenidate use. J Child
Neurol 2000; 15: 265-267.

Thank you for copying data from http://www.arastirmax.com